{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:16:10Z","timestamp":1788009370696,"version":"build-2784847793"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,29]]},"DOI":"10.7759\/cureus.115393","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T12:35:06Z","timestamp":1788006906000},"source":"Crossref","is-referenced-by-count":0,"title":["CAR-T Versus Non-CAR-T Bridging Strategies Before Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Omar","family":"Halloumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanae","family":"Sabbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Lahlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Fares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger T","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017, 7:e577. 10.1038\/bcj.2017.53","journal-title":"Blood Cancer J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01625-x","article-title":"The WHO classification of haematolymphoid tumours","volume":"36","author":"Cree IA","year":"2022","unstructured":"Cree IA. The WHO classification of haematolymphoid tumours. Leukemia. 2022, 36:1701-2. 10.1038\/s41375-022-01625-x","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33018-1","article-title":"Acute lymphoblastic leukaemia","volume":"395","author":"Malard F","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020, 395:1146-62. 10.1016\/S0140-6736(19)33018-1","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111356","article-title":"Global, regional, and national burden of acute lymphoblastic leukemia in children: epidemiological trends analysis from 1990 to 2021","volume":"27","author":"Hu Y","year":"2024","unstructured":"Hu Y, Liu Y, Fu J, Liu Y, Wang H, Song Y. Global, regional, and national burden of acute lymphoblastic leukemia in children: epidemiological trends analysis from 1990 to 2021. iScience. 2024, 27:111356. 10.1016\/j.isci.2024.111356","journal-title":"iScience"},{"key":"ref5","article-title":"","author":"Lalla Salma Foundation","year":"2024","unstructured":"Lalla Salma Foundation. Cancer Registry of the Greater Casablanca Region 2018-2021. Lalla Salma Foundation, Casablanca; 2024. https:\/\/www.contrelecancer.ma\/fr\/documents\/registre-des-cancers-de-la-region-du-grand-casab-4\/."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian H","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N, et al.. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017, 376:836-47. 10.1056\/NEJMoa1609783","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian HM","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M, et al.. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016, 375:740-53. 10.1056\/NEJMoa1509277","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184623","article-title":"Blinatumomab and inotuzumab ozogamicin sequential use for the treatment of relapsed\/refractory acute lymphoblastic leukemia: a real-life campus all study","volume":"15","author":"Fracchiolla NS","year":"2023","unstructured":"Fracchiolla NS, Scium\u00e8 M, Papayannidis C, et al.. Blinatumomab and inotuzumab ozogamicin sequential use for the treatment of relapsed\/refractory acute lymphoblastic leukemia: a real-life campus all study. Cancers (Basel). 2023, 15:4623. 10.3390\/cancers15184623","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu X","year":"2019","unstructured":"Xu X, Sun Q, Liang X, et al.. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019, 10:2664. 10.3389\/fimmu.2019.02664","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1048296","article-title":"CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory\/relapsed acute B lymphocytic leukemia: long-term follow-up results","volume":"12","author":"Li Z","year":"2022","unstructured":"Li Z, Yang K, Song Y, et al.. CAR-T therapy followed by allogeneic hematopoietic stem cell transplantation for refractory\/relapsed acute B lymphocytic leukemia: long-term follow-up results. Front Oncol. 2022, 12:1048296. 10.3389\/fonc.2022.1048296","journal-title":"Front Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.46658\/JBIMES-20-08","article-title":"Systematic reviews of etiology and risk","author":"Moola S","year":"2020","unstructured":"Moola S, Munn Z, Tufanaru C, et al.. Systematic reviews of etiology and risk. JBI Manual for Evidence Synthesis. Aromataris E, Munn Z (ed): Joanna Briggs Institute, Adelaide; 2020. 10.46658\/JBIMES-20-08"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.11124\/JBIES-23-00268","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies","volume":"22","author":"Barker TH","year":"2024","unstructured":"Barker TH, Habibi N, Aromataris E, et al.. The revised JBI critical appraisal tool for the assessment of risk of bias for quasi-experimental studies. JBI Evid Synth. 2024, 22:378-88. 10.11124\/JBIES-23-00268","journal-title":"JBI Evid Synth"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70108","article-title":"Bridging with chimeric antigen receptor T-cell therapy or chemotherapy to Allo-HSCT in B-ALL: a comparison of treatment complications and survival","volume":"116","author":"Wu N","year":"2026","unstructured":"Wu N, Kong J, Lv M, et al.. Bridging with chimeric antigen receptor T-cell therapy or chemotherapy to Allo-HSCT in B-ALL: a comparison of treatment complications and survival. Eur J Haematol. 2026, 116:615-24. 10.1111\/ejh.70108","journal-title":"Eur J Haematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06399-1","article-title":"Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed\/refractory B cell acute lymphoblastic leukemia","volume":"23","author":"Cao W","year":"2025","unstructured":"Cao W, Li N, Wang G, et al.. Efficacy and safety comparison of CAR-T and blinatumomab immunotherapy as bridge-to-transplant strategies in relapsed\/refractory B cell acute lymphoblastic leukemia. J Transl Med. 2025, 23:391. 10.1186\/s12967-025-06399-1","journal-title":"J Transl Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003396","article-title":"Comparison of blinatumomab and chimeric antigen receptor T cells pre-haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome negative B-cell acute lymphoblastic leukemia","volume":"138","author":"Hu G","year":"2025","unstructured":"Hu G, Suo P, Bai L, Zhang X, Cheng Y, Huang X. Comparison of blinatumomab and chimeric antigen receptor T cells pre-haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome negative B-cell acute lymphoblastic leukemia. Chin Med J (Engl). 2025, 138:472-4. 10.1097\/CM9.0000000000003396","journal-title":"Chin Med J (Engl)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1459","article-title":"CD19\/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and Epstein-Barr virus viremia after transplantation","volume":"13","author":"Li S","year":"2023","unstructured":"Li S, Ge J, Zhou S, et al.. CD19\/CD22 dual-targeting chimeric antigen receptor T-cell therapy bridging to allogeneic haematopoietic stem cell transplantation for B-cell acute lymphoblastic leukaemia delays platelet recovery and increases risks of cytomegalovirus and Epstein-Barr virus viremia after transplantation. Clin Transl Med. 2023, 13:e1459. 10.1002\/ctm2.1459","journal-title":"Clin Transl Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002764","article-title":"Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"136","author":"Zhao X","year":"2023","unstructured":"Zhao X, Wu H, Cheng Y, et al.. Bridging chimeric antigen receptor T-cell before transplantation improves prognosis of relapsed\/refractory B-cell acute lymphoblastic leukemia. Chin Med J (Engl). 2023, 136:2011-3. 10.1097\/CM9.0000000000002764","journal-title":"Chin Med J (Engl)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01845-w","article-title":"CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"58","author":"Yao Z","year":"2023","unstructured":"Yao Z, Gu B, Zhang Y, et al.. CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant. 2023, 58:103-5. 10.1038\/s41409-022-01845-w","journal-title":"Bone Marrow Transplant"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.934442","article-title":"Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy","volume":"13","author":"Yang TT","year":"2022","unstructured":"Yang TT, Meng Y, Kong DL, et al.. Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy. Front Immunol. 2022, 13:934442. 10.3389\/fimmu.2022.934442","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915590","article-title":"Comparisons of long-term survival and safety of haploidentical hematopoietic stem cell transplantation after CAR-T cell therapy or chemotherapy in pediatric patients with first relapse of B-cell acute lymphoblastic leukemia based on MRD-guided treatment","volume":"13","author":"Hu G","year":"2022","unstructured":"Hu G, Cheng Y, Zuo Y, et al.. Comparisons of long-term survival and safety of haploidentical hematopoietic stem cell transplantation after CAR-T cell therapy or chemotherapy in pediatric patients with first relapse of B-cell acute lymphoblastic leukemia based on MRD-guided treatment. Front Immunol. 2022, 13:915590. 10.3389\/fimmu.2022.915590","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.731435","article-title":"Chimeric antigens receptor T cell therapy improve the prognosis of pediatric acute lymphoblastic leukemia with persistent\/recurrent minimal residual disease in first complete remission","volume":"12","author":"Hu GH","year":"2021","unstructured":"Hu GH, Cheng YF, Zuo YX, et al.. Chimeric antigens receptor T cell therapy improve the prognosis of pediatric acute lymphoblastic leukemia with persistent\/recurrent minimal residual disease in first complete remission. Front Immunol. 2021, 12:731435. 10.3389\/fimmu.2021.731435","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.605766","article-title":"Integrating CAR T-cell therapy and transplantation: comparisons of safety and long-term efficacy of allogeneic hematopoietic stem cell transplantation after CAR T-cell or chemotherapy-based complete remission in B-cell acute lymphoblastic leukemia","volume":"12","author":"Zhao YL","year":"2021","unstructured":"Zhao YL, Liu DY, Sun RJ, et al.. Integrating CAR T-cell therapy and transplantation: comparisons of safety and long-term efficacy of allogeneic hematopoietic stem cell transplantation after CAR T-cell or chemotherapy-based complete remission in B-cell acute lymphoblastic leukemia. Front Immunol. 2021, 12:605766. 10.3389\/fimmu.2021.605766","journal-title":"Front Immunol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude SL","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al.. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018, 378:439-48. 10.1056\/NEJMoa1709866","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.145","article-title":"High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients","volume":"31","author":"Pan J","year":"2017","unstructured":"Pan J, Yang J, Deng B, et al.. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Leukemia. 2017, 31:2587-93. 10.1038\/leu.2017.145","journal-title":"Leukemia"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.02.006","article-title":"Sequential allogeneic HSCT after CAR-T therapy for relapsed\/refractory acute lymphoblastic leukemia patients: a long-term follow-up result","volume":"78","author":"Yang T","year":"2025","unstructured":"Yang T, Dong Y, Shi J, et al.. Sequential allogeneic HSCT after CAR-T therapy for relapsed\/refractory acute lymphoblastic leukemia patients: a long-term follow-up result. J Adv Res. 2025, 78:461-9. 10.1016\/j.jare.2025.02.006","journal-title":"J Adv Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25582","article-title":"Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial","volume":"94","author":"Jiang H","year":"2019","unstructured":"Jiang H, Li C, Yin P, et al.. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial. Am J Hematol. 2019, 94:1113-22. 10.1002\/ajh.25582","journal-title":"Am J Hematol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20180","article-title":"Higher risk of platelet engraftment failure and chronic GVHD after allo-HSCT following CAR-T therapy compared to chemotherapy","volume":"207","author":"Yang L","year":"2025","unstructured":"Yang L, Lai X, Liu L, et al.. Higher risk of platelet engraftment failure and chronic GVHD after allo-HSCT following CAR-T therapy compared to chemotherapy. Br J Haematol. 2025, 207:162-70. 10.1111\/bjh.20180","journal-title":"Br J Haematol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2023.1205","article-title":"CD19-specific CAR-T cell treatment of 115 children and young adults with acute B lymphoblastic leukemia: long-term follow-up","volume":"56","author":"Wang Y","year":"2024","unstructured":"Wang Y, Xue YJ, Zuo YX, Jia YP, Lu AD, Zeng HM, Zhang LP. CD19-specific CAR-T cell treatment of 115 children and young adults with acute B lymphoblastic leukemia: long-term follow-up. Cancer Res Treat. 2024, 56:945-55. 10.4143\/crt.2023.1205","journal-title":"Cancer Res Treat"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1980214","article-title":"Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow-up post-CD19 CAR-T therapy","volume":"63","author":"Chen M","year":"2022","unstructured":"Chen M, Fu M, Wang A, et al.. Cytoplasmic CD79a is a promising biomarker for B lymphoblastic leukemia follow-up post-CD19 CAR-T therapy. Leuk Lymphoma. 2022, 63:426-34. 10.1080\/10428194.2021.1980214","journal-title":"Leuk Lymphoma"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33937","article-title":"CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory\/relapsed B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu J","year":"2024","unstructured":"Liu J, Xu M, Zhang X, et al.. CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory\/relapsed B-cell acute lymphoblastic leukemia. Heliyon. 2024, 10:e33937. 10.1016\/j.heliyon.2024.e33937","journal-title":"Heliyon"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/523478-car-t-versus-non-car-t-bridging-strategies-before-allogeneic-hematopoietic-stem-cell-transplantation-in-relapsedrefractory-b-cell-acute-lymphoblastic-leukemia-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T12:35:07Z","timestamp":1788006907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/523478-car-t-versus-non-car-t-bridging-strategies-before-allogeneic-hematopoietic-stem-cell-transplantation-in-relapsedrefractory-b-cell-acute-lymphoblastic-leukemia-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.115393","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,29]]}}}